Minerva Neurosciences Inc. Daily Stock Analysis

Daily Stock Analysis, NERV, Minerva Neurosciences Inc, priceseries

Minerva Neurosciences Inc. Daily Stock Analysis
Stock Information
Open
0.67
Close
0.63
High
0.72
Low
0.63
Previous Close
0.67
Daily Price Gain
-0.04
YTD High
0.92
YTD High Date
Jan 3, 2022
YTD Low
0.63
YTD Low Date
Mar 7, 2022
YTD Price Change
-0.29
YTD Gain
-31.05%
52 Week High
3.54
52 Week High Date
May 18, 2021
52 Week Low
0.63
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-2.56
52 Week Gain
-80.12%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 25. 2017
7.65
Jun 22. 2017
9.57
19 Trading Days
25.11%
Link
LONG
Sep 1. 2017
6.45
Sep 20. 2017
7.14
12 Trading Days
10.62%
Link
LONG
May 17. 2018
7.40
Jun 4. 2018
8.51
11 Trading Days
14.97%
Link
LONG
Aug 15. 2018
8.50
Sep 10. 2018
9.90
17 Trading Days
16.48%
Link
LONG
Sep 14. 2018
10.50
Oct 1. 2018
11.75
11 Trading Days
11.92%
Link
LONG
Feb 7. 2019
6.85
Mar 6. 2019
7.78
18 Trading Days
13.62%
Link
LONG
Jun 27. 2019
5.46
Jul 16. 2019
6.42
12 Trading Days
17.53%
Link
LONG
Aug 29. 2019
6.90
Sep 24. 2019
8.24
17 Trading Days
19.40%
Link
LONG
Nov 19. 2019
5.56
Dec 17. 2019
7.02
19 Trading Days
26.34%
Link
LONG
Apr 9. 2020
5.85
May 28. 2020
13.06
33 Trading Days
123.30%
Link
LONG
Jan 6. 2021
2.49
Jan 29. 2021
3.07
16 Trading Days
23.30%
Link
LONG
May 13. 2021
2.69
May 25. 2021
2.99
8 Trading Days
11.23%
Link
Company Information
Stock Symbol
NERV
Exchange
NasdaqGM
Company URL
http://www.minervaneurosciences.com
Company Phone
617-600-7373
CEO
Rémy Luthringer
Headquarters
Massachusetts
Business Address
1601 TRAPELO ROAD, SUITE 284, WALTHAM, MA 02451
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001598646
About

Minerva Neurosciences, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company's product portfolio includes MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.

Description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The company' preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading